The senate ad-hoc committee appointed by Pro-tempore and tasked with reviewing the MedTech consultancy with the government has disclosed the completion of its work.
Taking to his official Facebook page in making the pronouncement on Saturday ,Gbarpolu County senator Amara Mohammed Konneh disclosed that that the Ad-hoc Committee, appointed by the Pro Tempore of the Liberian Senate, has completed a comprehensive investigation of the Destination Inspections Contract between the Government of Liberia and MedTech Scientific Limited.
Having already submitted its findings to the plenary on September 19, 2024 the Gbarpolu Senator said the investigation was intended to ensure that all procurement and execution of the contracts complied with legal and regulatory requirements, promote transparency in the contracting process, and evaluate ManTech’s performance and financial management practices.
He then concluded by adding that among other things, the ad-hoc committee’s report, include review findings and 10 recommendations to the President and Executive Branch, with implications for upholding the country’s laws, industry and commerce. Furthermore, it also discussed about boosting custom revenues.
Initial perusal of the report’s findings revealed several anomalies which are quite troubling and worth noting. For instance, there is no evidence of the establishment the LRA Concession committee as called for by the PPCA. Further, though the Committee made a request for concession certificate, neither was it presented nor evidence made available as requested by the committee. As if these infractions were not enough, there was no evidence of PPP concession certificate as stipulated in section 88 (2) of the PPCA.
Regarding the 10 tabled recommendations, the first 4 were found to be more thorough and very relevant as they bordered on either addressing all the observable shortcomings with the sole aim of recorrecting problems wrong with MedTech concession or terminating same. However, it is important to state that the Committee conducted what some observers are terming as excellent investigation but fell short of being pointed and direct in advising the Executive with respect to the route to proceed by either cancelling or renegotiating the now infamous MedTech concession; said decision has been left squarely within the purview of the President and the Executive Branch.
